Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lonsurf + Onivyde second-line therapy for advanced cholangiocarcinoma or gallbladder carcinoma
2024-517330-18-00Phase 2Authorised
- Sponsor
- Heinrich Heine University Düsseldorf
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trifluridine + tipiracil and irinotecan in cholangiocarcinoma (CCA), gallbladder cancer and biliary cancer, sponsored by Heinrich Heine University Düsseldorf. Primary endpoint: Median progression-free survival. Planned start Oct 2025; status: authorised.
02
Drugs
trifluridine + tipiracilirinotecan
03
Conditions
cholangiocarcinoma (CCA)gallbladder cancerbiliary cancer
Beyond the preview
Go deeper on 2024-517330-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517330-18-00.